Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis

Published:2014-07 Issue:4 Volume:12 Page:346-358
ISSN:2095-4964
Container-title:Journal of Integrative Medicine
language:en
Short-container-title:Journal of Integrative Medicine

Author:

Liu Zhong-liang,Zhu Wei-rong,Zhou Wen-chao,Ying Hai-feng,Zheng Lan,Guo Yuan-biao,Chen Jing-xian,Shen Xiao-heng

Publisher

Elsevier BV

Subject

General Medicine

Reference52 articles.

1. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for neversmokers with advanced or metastatic adenocarcinoma of the lung;Lee;San Francisco: 13th World Conference on Lung Cancer,2009

4. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study;Giaccone;Clin Cancer Res,2006

5. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer;Jackman;J Clin Oncol,2007

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gypenoside inhibits gastric cancer proliferation by suppressing glycolysis via the Hippo pathway;Scientific Reports;2024-08-16

2. Gypenoside Inhibits Gastric Cancer Proliferation by Suppressing Glycolysis via the Hippo Pathway;2024-03-28

3. A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations;Integrative Cancer Therapies;2024-01

4. Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort);Integrative Cancer Therapies;2023-01

5. Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash;Integrative Cancer Therapies;2023-01